Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy: Commentary

Nature Clinical Practice Urology

Volumn 5, Issue 7, 2008, Pages 362-363

  Klotz, Laurence ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

CALIBRATION; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTERNAL VALIDITY; MEDICAL DECISION MAKING; NOMOGRAM; ONSET AGE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SHORT SURVEY; SURVIVAL TIME; WATCHFUL WAITING;

EID: 51749125767     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1131     Document Type: Short Survey

References (5)

1. Bill-Axelson A et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977-1984
2. Studer UE et al. (2008) Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 53: 941-949
3. Klotz L (2005) Active surveillance for prostate cancer: For whom? J Clin Oncol 23: 8165-8169
4. Steyerberg EW et al. (2007) Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram. J Urol 177: 107-112
5. Nakanishi H et al. (2007) A nomogram for predicting low-volume/ low-grade prostate cancer: A tool in selecting patients for active surveillance. Cancer 110: 2441-2447